Kenn Holmbeck
Overview
Explore the profile of Kenn Holmbeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
2146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Worzner K, Schmidt S, Zimmermann J, Tami A, Polacek C, Fernandez-Antunez C, et al.
EBioMedicine
. 2025 Feb;
113:105615.
PMID: 39983329
Background: Intranasal vaccines against respiratory viruses are desired due to ease of administration and potential to protect against virus infection of the upper respiratory tract. Methods: We tested a cationic...
2.
Olesen C, Collignon L, Velazquez-Moctezuma R, Fanalista M, Fahnoe U, Mollerup S, et al.
Hepatology
. 2024 Oct;
PMID: 39378413
Background And Aims: Chronic HCV infection afflicts around 50 million people globally, causing ~250,000 deaths yearly. An effective vaccine needs to overcome high viral diversity and HCV's ability to evade...
3.
Offersgaard A, Duarte Hernandez C, Zhou Y, Duan Z, Gammeltoft K, Hartmann K, et al.
Sci Rep
. 2024 Jul;
14(1):17039.
PMID: 39048693
Rapidly waning immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires continued global access to affordable vaccines. Globally, inactivated SARS-CoV-2 vaccines have been widely used during the SARS-CoV-2 pandemic....
4.
Collignon L, Holmbeck K, Just A, Verhoye L, Velazquez-Moctezuma R, Fahnoe U, et al.
Hepatology
. 2024 Apr;
80(5):1227-1238.
PMID: 38652584
Background And Aims: HCV infection continues to be a major global health burden despite effective antiviral treatments. The urgent need for a protective vaccine is hindered by the scarcity of...
5.
Bajpai P, Collignon L, Solund C, Madsen L, Christensen P, Ovrehus A, et al.
J Virol
. 2023 Dec;
97(12):e0092523.
PMID: 38092564
HCV genotype 3b is a difficult-to-treat subtype, associated with accelerated progression of liver disease and resistance to antivirals. Moreover, its prevalence has significantly increased among persons who inject drugs posing...
6.
Sherwood A, Rivera-Rangel L, Ryberg L, Larsen H, Anker K, Costa R, et al.
Nature
. 2023 Jul;
619(7971):811-818.
PMID: 37407817
RNA viruses have evolved elaborate strategies to protect their genomes, including 5' capping. However, until now no RNA 5' cap has been identified for hepatitis C virus (HCV), which causes...
7.
Wolfisberg R, Holmbeck K, Billerbeck E, Thorselius C, Batista M, Fahnoe U, et al.
J Virol
. 2023 Mar;
97(4):e0181222.
PMID: 36971565
The lack of robust immunocompetent animal models for hepatitis C virus (HCV) impedes vaccine development and studies of immune responses. Norway rat hepacivirus (NrHV) infection in rats shares HCV-defining characteristics,...
8.
Offersgaard A, Hernandez C, Feng S, Marichal-Gallardo P, Holmbeck K, Pihl A, et al.
iScience
. 2023 Jan;
26(2):105949.
PMID: 36644321
Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity...
9.
Pham L, Velazquez-Moctezuma R, Fahnoe U, Collignon L, Bajpai P, Solund C, et al.
Viruses
. 2022 Nov;
14(11).
PMID: 36423136
Hepatitis C virus (HCV) genotype 4 is highly prevalent in the Middle East and parts of Africa. Subtype 4d has recently spread among high-risk groups in Europe. However, 4d infectious...
10.
Wolfisberg R, Thorselius C, Salinas E, Elrod E, Trivedi S, Nielsen L, et al.
Hepatology
. 2022 Apr;
76(5):1506-1519.
PMID: 35445423
Background And Aims: Lack of tractable immunocompetent animal models amenable to robust experimental challenge impedes vaccine efforts for HCV. Infection with rodent hepacivirus from Rattus norvegicus (RHV-rn1) in rats shares...